Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maxcyte Inc (NQ: MXCT )

4.140 +0.060 (+1.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 242,359
Open 4.080
Bid (Size) 3.900 (5)
Ask (Size) 4.400 (1)
Prev. Close 4.080
Today's Range 3.980 - 4.195
52wk Range 3.360 - 7.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga

Performance

YTD
-19.14%
-19.14%
1 Month
-12.47%
-12.47%
3 Month
-12.66%
-12.66%
6 Month
-32.90%
-32.90%
1 Year
-3.04%
-3.04%

More News

Read More
Recap: MaxCyte Q1 Earnings
Via Benzinga
Looking Into MaxCyte's Return On Capital Employed
Via Benzinga
MaxCyte's Earnings: A Preview
Via Benzinga
Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Earnings Perspective: Return On Capital Employed
Via Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
Via InvestorPlace
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
From MaxCyte, Inc
Via GlobeNewswire
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Earnings Scheduled For March 15, 2023
Via Benzinga
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
7 Must-Buy Penny Stocks to Add to Your Portfolio in 2023
Via InvestorPlace
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
From MaxCyte, Inc
Via GlobeNewswire
7 Hot Stocks to Book Profits In Before 2023
Via InvestorPlace
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Third Quarter 2022 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
Earnings Outlook For MaxCyte
Via Benzinga
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.